Browse by Topic

(1-324) Implementation of Standard Operating Procedures for Radiology Order Review

(1-342) All Hands-on Deck! Standardizing Substance Use Disorder Care Infrastructure in an Integrated Healthcare System

(2-030) Retrospective Analysis of Partial Fill Prescription Processing at a Veterans Affairs Medical Center (VAMC)

(2-035) Descriptive Review of the Formulation Conversion of Inhaled Corticosteroid/Long-Acting Beta-Agonist (ICS/LABA) Inhalers at a Veterans Affairs Medical Center

(2-095) Cost-Utility Analysis of Academic Detailing Outreach on Naloxone Prescribing for Patients at Risk of Opioid-Related Overdose

(2-119) Guiding Central Inventory Optimization in an Inpatient Community Hospital Pharmacy

(2-134) Proposal to Remove Rifaximin 550mg Tablets from Formulary in Favor of 200mg Tablets at Hartford Healthcare

(2-142) Assessing Covid-19 Vaccine Waste in a Healthcare System

(3-056) U.S. Schools of Pharmacy Application and Expense Landscape and the Effect of COVID-19

(3-102) Implementation of 5S Methodology in a Central Pharmacy at a Large Academic Hospital

(3-124) National Strategies to Optimize Taiwan's Drug Supply Chain and Mitigate Drug Shortages Amid COVID-19 Pandemic

(3-137) Integration of Pharmacy Students into Clinical Internships in the Workplace

(5-255) A Systematic Review of Emerging Alternative Payment Models (APMs) Used for Oncologic Treatment in the United States

(3-246) Comprehensive Pharmacist-led Transitions-of-care Medication Management Intervention for Older Adults Around Hospital Discharge: A Time-and-Motion Analysis of Resources and Costs

(3-291) Where to Go When You Need to Know?: A Meds to Beds Tool to Improve Visibility of Order Progress

(4-001) Impact of Par Adjustments on Inventory Turnover Ratios at an Ambulatory Infusion Center

(4-002) Implementation of Centralized Product Defect Reporting for Cost Recovery Across Campuses

(4-003) Planning and Relocation of the Pharmacy of a Mother-child University Health Center

(4-004) Survey of Hospital Pharmacy Practice in Canada – 1985-86 to 2020-21

(5-025) Evaluation of Differences in Payer-negotiated Prices Between Biosimilars and Originator Drugs

(5-026) Enhancing Resident-Preceptor Relationships Through Resilience Discussions

(5-050) Therapeutic Interchange of Rifaximin in Acute Overt Hepatic Encephalopathy

(5-062) Alvimopan Utilization Analysis: Opportunities for Pharmacist Intervention in a Large Community Hospital

(5-151) An Analysis of COVID-Impacted Rutgers Pharmaceutical Industry Fellowship (RPIF) Interview Strategies and Perceptions: In-Person versus Virtual

(5-221) Implementation of Epic Willow Dispense Prep for Non-Sterile Preparations

(6-027) Evaluation of Controlled Substance Infusion Storage in Refrigerated Automated Dispensing Cabinets in an Academic Medical Center

(6-076) Effects of DIR Fees on Independent Community Pharmacies in North Dakota

(6-180) Increasing Community Access to Naloxone Through Training and Equipping Hospital Security Officers

(6-190) Evaluation of Intravenous Albumin Use at a Six-Hospital Health System

(6-236) Financial Impact Associated with Hiring Internal Pharmacy Residents Post-Graduation

(7-005) Alteplase vs Tenecteplase: Make the Switch? A Retrospective Review of Purchase Volume and Conversion

(7-052) Creation and Standardization of Inpatient Pharmacy Department’s Quality Assurance Program

(7-058) Potential Cost-Savings by Implementing Changes to Standard Selenium Dosing in Neonatal and Pediatric TPN Formulations for a Hospital Network

(7-062) Waste Impact of Transitioning from Patient-specific Compounding to Batch Compounding Non-Sterile Oral Syringes into Automated Dispensing Cabinets (ADC)

(7-068) Optimization of the Therapeutic Interchange in Epic

(7-069) Implementation of a Sterile Preparation Operations Team in an Academic Healthcare System

(7-070) Survey-Based Analysis of Quality Improvement: Transitioning Pharmacy Experiential Rotation Management Systems

(7-071) Cost Impact Analysis for Management of Hepatitis C Virus: Evaluation of Patient Medications Assistance Program (PMAP) at a University Health System

(7-098) Onsite vs. Virtual Prospective College of Pharmacy Student Performance in Multiple-Mini Interviews (MMI)

(7-112) Implementation of a Demand Forecasting Model for Premixed Sterile Compounded Products

(7-113) Biologic Use in Oncologic and Non-Oncologic Indications: Patient Safety and Satisfaction

(7-175) Pharmacist Licensure- demographics, Awareness, and Perceptions in Utah

(6-095) A New Upgrade: Rebooting an Order Processing Workflow for an IV Chemotherapy Compounding Robot

(7-243) Assessment and Evaluation of Inpatient Pharmacist Staffing Models

(7-276) Innovative Technology for Optimized Pharmaceutical Pricing Standardization Across a Large Health System

(7-303) Prescription Cost Analysis and Utilization of Cost-Savings Opportunities at Saturday Clinic for the Uninsured

(7-325) Optimizing an Infliximab Administration Protocol to Safely Reduce Infusion Time and Improve Patient Satisfaction

(8-061) Optimizing Package Sizes to Reduce Waste of Single-Dose Medications with Weight-Based Dosing

(8-068) “Meeting DSCSA Compliance Requirements and Creating Strategic Value – One Health System’s Journey”

(8-071) National Strategies to Optimize Taiwan's Drug Supply Chain and Mitigate Drug Shortages Amid COVID-19 Pandemic

(8-072) Two Year Retrospective Comparison of COVID-19 Cases and Drug Expenditure Trends at Five Community Hospitals

(9-128) Implementation of a Payment Model to Encourage Cost Effective Prescribing of VEGF Inhibitors for AMD in an IPA

(9-168) Implementation of a Multidisciplinary Controlled Substance Diversion Prevention Program at an Academic Health System

(9-181) Would Improving the Medication Delivery Process Reduce Missing Medications and Delay in Patient Care at an Inpatient Hospital?

(9-220) Evaluation of I.V. Room Batching Process and Implementation of Interventions to Improve Efficiencies in an Institutional Setting

(9-232) Optimizing Value Capture Through an Automated Contract Pricing Surveillance Process

(10-072) Evaluation of Revenue Lost from Medications Administered by the Anesthesia Department in Areas Without an Automated Dispensing System

(10-235) Optimizing Workflow for Sterile Compounding Pharmacy Technicians in an Inpatient Pharmacy

(10-406) Employing a Drug Diversion Committee to Tackle Diversion in Health Systems

(11-034) Allergy Verification: A Process of Improvement

(11-037) Investigation of Narcotic Discrepancy Trends Associated with Automated Dispensing Cabinets (ADCs)

(11-089) Implementation of a Pharmacy Quality Improvement Plan

(11-146) Evaluating the Impact of Collaborative Bedside Teams Involving Pharmacist Driven Medication Administration Compared to Standard Care on Medical Surgical Units

(11-400) Development of a Business Plan for Pharmacist-Led Inpatient Anticoagulation Management

(11-413) Analysis of Nonsterile Compounded Medications at an Academic Medical Center

(12-057) A Multidisciplinary Team Approach to Oncology Drug Utilization Management at a Community Cancer Center

(12-247) Establishing a System Wide Policy for the Management of Investigational Drugs in Samaritan Health Services, OR

(13-094) Investment Analysis of Residency Trained Pharmacist

(13-098) Evaluating the Perceptions of Pharmacists and Pharmacy Technicians Pre- and Post- Implementation of a Tech-Check-Tech Program in an Inpatient Pharmacy Setting

(13-113) Health System Experience of Adding a Home Infusion Service Line-Impact on Patient and Provider Experience

(13-212) What Factors Cause Pharmacy Technicians to Stay or Leave a Job?

(13-301) Single Entity Integration: Child Site Incorporation and 340B Projections

(13-309) Evaluation of Text Message Utilization and Mail-Order Pharmacy Use on Medication Adherence

(13-351) Improving Departmental Communication Within an Inpatient Pharmacy Through Process-Oriented Interventions

(13-352) The Cost-Benefit Analysis of Implementing Intravenous Push Antibiotics at St. Peter Hospital

(13-360) Impact of Pharmacy Initiatives in Streamlining Authorization Processes in Outpatient Infusion Clinics

(13-363) Evaluation of Pharmacy Team Member Role in Decreasing Insurance Denials and Write-Offs of High-Cost Medications in Outpatient Infusion Clinics

(13-420) Optimizing an Automated Inventory Management Program at a Small Community Hospital

(1-009) Impact of an Updated Post Discharge Nursing Note Template on Continuation of Care

(1-013) Evaluation of Vitamin B12 Monitoring for Patients on Metformin at a Veteran Affairs Medical Center

(1-022) Developing, Implementing, and Assessing an Ambulatory Care Clinic Pharmacist Training Program for a National Clinical Pharmacy Specialist Clinic

(1-034) Population Health Management: Assessing Uptake of Evidence-based Therapies for Heart Failure in a Rural Community

(1-035) Evaluation of Gout Management for Patients on Oral Gout Prophylaxis at a Large Veterans Affairs Medical Center

(1-036) Utilization of Concomitant Anti-Inflammatory Prophylaxis with Urate-Lowering Therapy Initiation in a Veteran Population

(1-037) Evaluating Changes in Clinical Outcomes in Veterans Converted from Liraglutide to Semaglutide

(1-038) Transitions of Care in Patients with Diabetes and Peripheral Vascular Disease

(1-039) Evaluation of Guideline Directed Therapy for Veterans with Type II Diabetes and Chronic Kidney Disease with Concomitant Albuminuria

(1-042) Impact of Clinical Pharmacy Interventions to Improve Guideline-Directed Therapy in Patients with a Hemoglobin A1C Greater Than 9 Percent

(1-050) Evaluation of Cardiovascular, Renal and Safety Outcomes for Empagliflozin in the VA Central California Health Care System Population

(1-058) Evaluation of Semaglutide Efficacy in Patients with Type 2 Diabetes Mellitus in a Veterans Affairs Healthcare System

(1-064) Continuous Glucose Monitoring Devices and Blood Glucose Control in Veterans with Type 2 Diabetes

(1-069) Evaluation of the Use of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors in Combination with Diuretics in an Outpatient Veterans Affairs Population

(1-070) Evaluation of Safety Outcomes Following Conversion of Formulary-Preferred Inhaled Corticosteroid/Long-Acting Beta-2 Agonist Inhalers in a Veterans Affairs Population

(1-074) Evaluation of the Protective Factors of Pre-diabetes Among Underserved Patients: A Retrospective Cohort Study

(1-089) Evaluation of DPP-4i Use and Optimization of Diabetic Regimen Through the Use of a Population Management Tool in a Veteran Population with Heart Failure

(1-090) Pharmacist-Led Interventions to Optimize Diabetes Management in Adults with HbA1c Levels Above 9%

(1-094) Implementation of Pharmacist-Initiated Proton Pump Inhibitor (PPI) Deprescribing for Ambulatory Care Patients in a Veterans Affairs Healthcare System

(1-098) Identifying and Evaluating Patients with Type 2 Diabetes and Chronic Kidney Disease for Use of Finerenone

(1-101) Optimizing Surveillance of Patients with Cirrhosis in a Department of Veterans Affairs Health System

(1-102) Evaluating Clinical Pharmacy Technicians and Their Impact on Optimizing Clinical Pharmacist Practitioner Roles and Patient Care Within Anticoagulation and Primary Care Aligned Team (PACT) Clinics

(1-106) Pharmacist-led Continuous Glucose Monitor Management: Time Spent and Impact on Patient Care

(1-109) Assessing Insulin Requirements and Weight Change After Addition of Glucagon-like Peptide Receptor Agonists in the Treatment of Veterans with Type 2 Diabetes

(1-111) Clinical Impact of Implementation of the Diabetes Distress Score Tool on Type 2 Diabetes Management in VA Outpatient Clinics

(1-112) Effect of Statins on Cognition in Veterans with Type 2 Diabetes

(1-115) Long-Term Assessment of Weight Loss Medications in a Veteran Population

(1-124) Prescribing, Supplementation, and Monitoring of Oral Bisphosphonates for the Treatment of Osteoporosis in Veteran Patients: A Retrospective Study

(1-134) Impact of Hemoglobin A1c on Risk of Developing Urinary Tract and Genitourinary Infections Among Veterans Taking Sodium-glucose cotransporter-2 Inhibitors

(1-136) Impact of Pharmacist Driven Interventions on HIV Pre-Exposure Prophylaxis Initiation, Retention and Laboratory Compliance

(1-141) Tolerability of Empagliflozin in Older Adults

(1-142) Effect of the Home-Based Primary Care Blister Pack Program on Hypertension Outcomes in a Veteran Population

(1-146) Efficacy of Switching to Alternate Tumor Necrosis Factor-Alpha Inhibitor in Veterans with Psoriasis or Psoriatic Arthritis Who Experienced Treatment Failure

(1-147) Veteran Experiences with Hybrid Closed Loop (HCL) Insulin Pumps for Type 1 Diabetes (T1D) Management

(1-150) Reducing Delay of Elective Surgery via Intensive Preoperative Diabetes Management with Assistance of Personal Continuous Glucose Monitors, an Exploratory Study

(1-151) Implementation and Impact of a Pharmacist-Led Ambulatory Care Asthma Clinic

(1-155) Integrating Opioid Use Disorder (OUD) Treatment into Primary Care

(1-161) Evaluation of Unsuccessful Conversions from Budesonide/Formoterol to Fluticasone/Salmeterol in Veterans at the Kansas City Veterans Affair Medical Center (KCVAMC)

(1-162) PHASER Impact on Statin Prescribing

(1-168) Impact of Pharmacist Interventions in the Management of Prediabetes

(1-173) Implementation of a Pharmacist Managed Specialty Endocrine Satellite Clinic in a Veterans Affairs Ambulatory Care Clinic

(1-178) Evaluation of Transgender Pharmacotherapy at VA Sierra Nevada Health Care System

(1-179) Chronic Obstructive Pulmonary Disease Exacerbation Medication Kits for High-Risk Patients Receiving Home-Based Primary Care Within the Sierra Nevada Veteran Affairs Medical Center

(1-184) Implementation of Alcohol Use Disorder (AUD) Interventions in the Patient Aligned Care Team (PACT) Pharmacy Setting

(1-190) Evaluating the Utilization of Omega-3-Fatty Acids at Crownpoint Service Unit

(1-191) Implementing Hyperlipidemia and Hypertension Management into a Pharmacist-Led Diabetes Management Clinic

(1-193) Impact of Semaglutide And/or Empagliflozin on Hemoglobin A1c in the American Indian/Alaskan Native Population

(1-194) Implementing 2019 Global Initiative for Asthma Guideline Directed Prescribing at the Crownpoint Service Unit in the Navajo Nation

(1-195) Rethinking Omeprazole Prescribing Through Medical Staff Education and Technological Interventions at an Urban American Indian/ Alaskan Native Ambulatory Clinic

(1-201) Resistant Hypertension Prescribing Patterns at a Veterans Affairs Medical Center

(1-204) Impact of Telemedicine on Glycemic Control in Patients with Type 2 Diabetes Mellitus (T2DM)

(1-205) Impact of Pharmacist Intervention on Comprehensive Diabetes Management

(1-206) Evaluating Effectiveness of Pharmacy Intervention in Initial Smoking Cessation Counseling in Patients Who Are Current Smokers at Northport Veteran's Affairs Medical Center (VAMC)

(1-216) Implementation of Pharmacist-Led Levothyroxine Monitoring and Management in a Veteran Population

(1-218) Sodium-Glucose Cotransporter-2 Inhibitor Therapy in Veterans with Heart Failure with Reduced Ejection Fraction Regardless of Diabetes Status

(1-222) Evaluation of a Pharmacist-led Home Blood Pressure Monitoring Program at a Rural Midwestern Indian Health Service Clinic

(1-225) Evaluation of the Utilization, Safety, and Efficacy of Continuous Glucose Monitor Use at the Cincinnati VA Medical Center

(1-228) Evaluation of the Effect of Glucagon-Like Peptide-1 Analogues in Weight Management and Type 2 Diabetes Mellitus Control

(1-232) Optimizing the Storage and Utilization of Long-Acting Injectable Antipsychotics Within the VA Central Ohio Healthcare System

(1-233) Implementing Process Improvement for Offering Naloxone to Veterans Identified at Risk of Opioid Overdose Within Pharmacist-led Clinics

(1-236) Implementation of a Medication Assisted Treatment Program in a Pharmacist Managed Ambulatory Clinic

(1-246) Comparing Low Dose (Microdosing) versus Traditional Dosing of Buprenorphine/Naloxone for Patients with Opioid Use Disorder

(1-248) Impact of Clinical Pharmacist Management in Patients with Uncontrolled Diabetes Mellitus

(1-258) Weight Management Medications for Chronic Use Medication Use Evaluation

(1-259) Evaluation of Fluticasone/Salmeterol Dry Powder Inhaler versus Budesonide/Formoterol Metered Dose Inhaler in the Management of Chronic Obstructive Pulmonary Disease Among Veterans

(1-261) Assessing the Clinical Impact of Pharmacist Home Visits for Veterans Enrolled in Home-Based Primary Care

(1-263) The Effectiveness of Clinical Pharmacy Practitioner Management of Glycemic Control Among Outpatient Veterans with Type 2 Diabetes

(1-266) A Pharmacist’s Impact in the Medication Optimization for Veterans with Heart Failure with a Reduced Ejection Fraction

(1-268) Implementation of a Pharmacist-Monitored Dashboard for Discrepant Urine Drug Screens

(1-269) Impact of a Pharmacist Run Clinic on Diabetes Management at an Indian Health Service Site

(1-271) Outcomes of an Inhaled Corticosteroid De-escalation Initiative Among Outpatient Veterans with Chronic Obstructive Pulmonary Disease

(1-272) Pharmacist-Led Initiative to Increase Guideline-Directed Medical Therapies (GDMT) in Veterans with Peripheral Arterial Disease (PAD)

(1-282) Implementation of the Hypoglycemia Safety/Choose Wisely (National VA Initiative) in Patient Aligned Care Team

(1-283) Efficacy and Safety of Semaglutide versus Dulaglutide in a Veterans Affairs Healthcare System

(1-284) Suicide-related Events Among the Use of Glucagon-like peptide-1 Receptor Agonists in a Veteran Population

(1-290) Uric Acid Monitoring Practices in Patients with Gout

(1-294) Identifying and Reducing Barriers to Clozapine Use at a Veteran Affairs Outpatient Mental Health Clinic

(1-295) Improving Low Complexity Mental Health Services Among Primary Care Providers in an Outpatient Veterans Affairs Clinic

(1-299) Evaluation of Statin-Associated Muscle Symptoms in Patients Initiated on Statin Therapy While Simultaneously Repleting Vitamin D Levels at a Veterans Affairs Medical Center

(1-300) National Veterans Affairs Hypoglycemic Safety Initiative Implementation at a Community Based Outpatient Clinic

(1-302) Effect of Pregabalin Initiation on Diuretic Requirements in Veterans with Chronic Heart Failure

(1-303) Tolerability of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Patients Receiving Hydralazine and Isosorbide Dinitrate

(1-306) Evaluation of Glucose Control with a Continuous Glucose Monitor in Veterans with Type II Diabetes

(1-309) Effect of Addition of the Sodium-glucose cotransporter-2 Inhibitor Empagliflozin on Diuretic Dosing in Patients Taking a Loop Diuretic

(1-310) Continuous Glucose Monitoring Impact on Glycated Hemoglobin Test (HbA1c) Trends in Geriatric Patients

(1-314) Treating Retinopathy Screenings as a Vital Sign for Diabetics at the Pharmacy

(1-316) Improving Semaglutide Weight Documentation After Implementing Formulary Criteria for Use Renewal and Provider Education

(1-323) Implementation of the Veterans Affairs National Hypoglycemia Safety Initiative Dashboard in a Primary Care Setting at the Washington DC Veterans Affairs Medical Center

(1-326) Effect of Continuous Glucose Monitoring on A1c Reduction and Hypoglycemia Prevention in a Real-World Veteran Population with Diabetes

(1-327) Knowledge and Stigma of Syringe Service Programs: A Survey of Clinicians and Ancillary Workers at a Level 1c Veterans Affairs Medical Center

(1-331) Evaluation of the Safety of De-Prescribing Inhaled Corticosteroids in Veterans with Mild-to-Moderate Chronic Obstructive Pulmonary Disease

(1-332) Assessing the Impact of Enhanced Integration of Clinical Pharmacist Practitioners (CPP) in Patient Aligned Care Teams

(1-333) Primary Care Provider Perceptions of Osteoporosis Treatment and Fidelity to National Osteoporosis Treatment Guidelines at the William S. Middleton Memorial Veterans Hospital

(1-337) Impact of Advanced Comprehensive Diabetes Care (ACDC) Telehealth Program on Glycemic Control in Veterans with Type 2 Diabetes Mellitus

(1-339) Pharmacist-Managed Inhaled Corticosteroid De-escalation in Patients with Stable COPD at a Veterans Affairs Medical Center

(1-343) Transitioning an Outpatient Dialysis Clinic from Patient-specific Orders to Floor Stock

(1-344) Pharmacist-led Deprescribing in Polypharmacy Patients at a Rural Veterans Affairs Healthcare System

(2-005) Treatment of Hepatitis C in an Indigent Population

(2-006) Introductory Pharmacy Practice Experience (IPPE) Students’ Changes in Knowledge, Attitudes, and Perceptions in Managing the Medical Care of Patients with Health Disparities

(2-007) Analysis of Fourth Year Student Pharmacists’ Perceptions of Health Disparities Before and After APPE Learning Experiences at Underserved Outpatient Clinical Practice Sites

(2-008) Optimizing Pain Management in the Community Pharmacy Setting Utilizing Preemptive Pharmacogenomic Screening of CYP2D6 and CYP2C9

(2-036) Prepping for PrEP: Evaluating the Impact of an Educational In-service on PrEP Therapy

(2-037) Retrospective Review of a Pharmacist-Managed Transitions of Care Service at a Federally Qualified Health Center: Financial and Clinical Outcomes

(2-038) Evaluation of Pharmacist-led Medicare Annual Wellness Visits to Satisfy Quality Metrics and USPSTF Recommendations After Implementation of a Post-Visit Follow-Up Protocol

(2-039) Evaluation of Clinical Outcomes with Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) Therapy in a Predominantly Underserved Patient Population

(2-054) Observational Assessment of Predictors of Stool DNA Testing and Up-To-Date Screening of Colorectal Cancer

(2-055) Predictors of Exercise Engagement Among U.S. Residents Diagnosed with Myalgia

(2-057) Association of Social Stability with Illicit Drug Use

(2-064) Pharmacist Led Interventions in Hepatitis C Management

(2-084) Investigating Hemoglobin A1C Change in Patients Who Are Referred to an Ambulatory Care Pharmacist in the Outpatient Setting

(2-099) Pediatric Cystic Fibrosis Pharmacist Clinic Visit Outcome Analysis: A Four-Year Follow-Up

(2-118) Characteristics of Patients Treated with Romosozumab as Compared to Parathyroid Hormone Analogs

(2-122) Impact of a Pharmacy Intern in a Heart Failure Clinic

(2-123) Evaluation of the Effectiveness of a Pharmacist-Led Diabetes Management Protocol on A1c Reduction in Patients with Uncontrolled Diabetes

(2-124) Retrospective Evaluation of the Effectiveness of a Clinical Pharmacy Driven Quality Improvement Initiative Targeting Blood Pressure Control

(2-150) Evaluation of Pharmacist Interventions to Initiate Continuous Blood Glucose Monitoring in Patients at a Federally Qualified Health Center

(2-151) Evaluation of Guideline-Directed International Normalized Ratio Goal for Outpatient Anticoagulation Management

(2-161) Monitoring Outpatients on Amiodarone Therapy at the James A. Haley Veterans’ Hospital (JAHVH)

(2-187) An Evaluation of Pharmacist Interventions Within a Primary Care Clinic on 30 and 90 Day Heart Failure Readmission Rates

(2-207) High-Evidence Actionable Pharmacogenomics in a Multispecialty, Tertiary Care Clinic

(2-208) The Prescribing Patterns of Urinary Tract Infection Management in Adult Patients at a Free Student-Run Free Clinic: A Retrospective Study

(2-220) Evaluation of CHA2DS2-VASc in Atrial Fibrillation Patients Receiving Anticoagulation in the Outpatient Setting

(2-248) Mental Health Trends in Transgender Adults Receiving Gender-Affirming Hormone Therapy at a Student-Run Free Clinic

(2-275) Establishing an Interprofessional and Collaborative Continuous Glucose Monitoring Service in a Family Medicine Graduate Medical Education Clinic

(2-282) Evaluating Hyponatremia in Patients Receiving Sodium Glucose Co-Transporter 2 Inhibitors (SGLT-2i)

(2-294) Effect of Prescribing GLP-1 Agonists on Weight and Insulin Dose in Patients Maintained on Insulin Therapy

(2-300) Evaluating Synagis Usage in an Outpatient Setting

(2-301) Evaluation of Combination Opioid and Benzodiazepine Therapy in Spinal Cord Injury Patients Treated with a Benzodiazepine for Spasticity Management at a Veterans Affairs Medical Center

(2-302) Evaluation of a Chronic Care Management Pilot Project and Revenue Projections for Sustainability

(3-012) Examining Prevention Quality Indicators (PQI), Cost, and Length of Stay for Diabetes Across Counties in Hawai’i

(3-013) Obesity and Diabetes Correlation and the Pharmacist’s Role in Diabetes Prevention Programs

(3-014) Evaluation of Lipid-Lowering Regimens in Patients with Diabetes Mellitus

(3-015) Comparison of Medicare Statin Prescribing and Stroke Deaths in the United States from 2017 to 2019

(3-017) Assessing the Use of Insulin and Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in a Primary Care Clinic

(3-020) Impact of Pharmacist-Led Medication Reconciliation on a Pediatric Outpatient Population

(3-045) Assessing Adherence to Guideline Recommendations on Initial Selection of Pharmacological Treatment for Hypertension at a General Internal Medicine Clinic in Metropolitan Central Illinois

(3-057) Sucralfate Slurry for the Treatment of Gastric Ulcers in a Patient with Dysphagia

(3-059) Coronavirus Disease 2019 (COVID-19) Vaccination Rates Among Incarcerated Patients with Hepatitis C Virus (HCV) Infection

(3-065) Outpatient Pharmacy Management of Dispensing Extended-Release Injectable Buprenorphine for Opioid Use Disorder at a Federally Qualified Health Center

(3-069) Evaluation of Ambulatory Care Pharmacist-led Nirmatrelvir/Ritonavir Prescribing on Rates of Hospitalization for COVID-19

(3-094) Efficacy of Transitions of Care Management (TCM) Services in Reducing Hospital Readmission Rates

(3-095) Diabetic Services Surveys

(3-131) Assessing Visitors’ Satisfaction of Smoking Cessation Clinics and Services: A Cross-sectional Study in Saudi Arabia

(3-135) Accuracy of A1c Testing When Conducted Through Capillary Point-of-care Testing Machines as Compared to Venous Blood Draw

(3-143) Improving Pharmacist Efficiency and Efficacy in Hypertension Management with Use of a Remote Blood Pressure Monitoring System​

(3-208) Pharmacists' Role in Improving Outcomes for Diabetic Neuropathy

(3-225) Evaluation of Appropriateness of Guideline Directed Medical Therapy in Chronic Heart Failure Patients Admitted to Observational Unit in a Community Hospital

(3-237) Missed Opportunities for Optimization of Cholesterol Management in Clinical Atherosclerotic Cardiovascular Disease

(3-247) Assessing the Impact of Social Determinants of Health in Patients with Opioid Use Disorder in the Primary Care Setting

(3-262) Transition to Once Weekly Tirzepatide After Severe Nausea and Vomiting One Year After Successful Treatment with Both Semaglutide and Exenatide LAR Once Weekly

(3-263) Pravastatin for Radiation-Induced Fibrosis Pain

(3-264) Evaluating Health Outcomes Associated with Concordant Language Interactions Between Diabetic Hispanic Patients and Providers

(3-274) Hydrochlorothiazide-Induced Pulmonary Edema: Case Report

(3-282) Finerenone and Empagliflozin Use for Chronic Kidney Disease with Albuminuria in a Patient with Type 2 Diabetes and Hypertension

(3-309) Effect of Pharmacist-Led Interventions on Diabetes Distress Among People with Type 2 Diabetes in a Community Care Setting

(4-005) Correction of Warfarin Coagulopathy for Non-bleeding Patients in the Outpatient Setting at an Ambulatory Care Organization: Application of Vitamin K Guidance

(4-006) Patient Satisfaction with Point of Care Testing (POCT) for Hemoglobin a1c (HbA1c) at an Academic Medical Center Serving a Rural Population

(4-007) Characterization of the New Orleans Syringe Access Program (NOSAP) Participants During the Initial Months of the Coronavirus Disease 2019 (COVID-19) Naloxone Education and Distribution Services

(4-008) Financial Reimbursement and Productivity Metrics for Pharmacist-led Chronic Care Management Services in Rural Practice Settings

(4-009) Glycemic Impact of Janus Kinase Inhibitors in Diabetic Patients with Immune-mediated Rheumatic Diseases

(4-010) Implementation and Outcomes of a Collaborative Drug Therapy Management Program in a Large Public Health Care System in the United States

(5-005) Implementation of a Primary Care Opioid Stewardship Team Reduces Morphine Milligram Equivalents in Patients on Chronic, High-Dose Opioid Therapy

(5-027) Resident Physician Perceptions, Expectations, and Experiences with Ambulatory Care Pharmacists and the Services Provided in Outpatient Clinics at a Large Academic Medical Center

(5-044) Evaluation of Prescribing Patterns for Sodium-Glucose Cotransporter Protein 2 (SGLT2) Inhibitors in a Primary Care Medicine Clinic

(5-082) Evaluation of Pharmacist-Led Intervention to Improve Access to Glucagon Emergency Devices

(5-094) Impact of a Student Pharmacist-Led Initiative to Improve Statin Use in Diabetes

(5-133) Designing a Protocol to Remotely Control Hypertension in Concurrent Disease

(3-010) 2020 Heart Disease Deaths Compared to Medicare Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease Inhibitor (PCSK9i) Prescription Rates

(5-170) Bicalutamide: Prostate Carcinoma Medication Being Used for Gender Affirming Care

(5-179) Comparative Efficacy of Patiromer and Sodium Zirconium Cyclosilicate in Patients with Mild-to-Moderate Hyperkalemia

(5-209) Baseline Population and Service Assessment to Implement Diabetes Self-Management Education and Support in a Community Pharmacy

(5-216) Remote Blood Pressure Monitoring Program in an Urban Clinic: A Single-Centered, Retrospective, Quality Improvement Project

(5-227) Evaluation of Access to Helicobacter pylori Treatment in Newly Resettled Refugees with a Pharmacist-led Multidisciplinary Team

(5-229) Identification of the Need to Develop Guidance for Therapeutic Conversions from GLP-1 Agonists to the Combined GIP/GLP-1 Agonist Tirzepatide

(5-270) Gauging the Impact of COVID-19 on Chronic Disease Treatment Through a Pharmacotherapeutic Lens

(5-282) Evaluation of a Multidisciplinary Approach to the Treatment of Latent Tuberculosis in Refugee Patients in the Primary Care Setting

(6-014) Impact of Direct Pharmacist Intervention on Hemoglobin A1c in Patients with Type II Diabetes Mellitus: A Retrospective Chart Review

(6-026) Outcomes of Pharmacist-Managed Tobacco Cessation Interventions in a Family Medicine Clinic

(6-042) Evaluation of a Systematic Prescribing Protocol for Continuous Glucose Monitoring (CGM) Devices Within a Family Medicine Practice

(6-043) Review of Student Pharmacist Involvement in Fulfilling Statin Use in Persons with Diabetes Quality Metric Within Atrium Health with a Focus on Statin Initiation

(6-044) Evaluation of Provider Satisfaction with Pharmacist-led Outreach Following Antidepressant Initiation in a Rural Primary Care Clinic

(6-045) Evaluation of Glycemic Control in Patients with Diabetes Utilizing Continuous Glucose Monitoring

(6-069) Review of Outcomes Associated with Patient Assistance Program Pharmacy Technicians

(6-070) Review of Student Pharmacist Involvement in Fulfilling Statin Use in Persons with Diabetes Quality Metric Within Atrium Health with a Focus on Exclusion Billing Codes

(6-071) Evaluation of Patient Satisfaction and Clinical Experience with an Automated Insulin Delivery System

(6-077) Pharmacist Call to Improve Treatment for Opioid Use Disorder

(6-078) Offering Preventative Care Incentives: Impact on Hepatitis Screening Numbers at a Federally Qualified Health Center Based Pharmacy

(6-082) Implementation of a Team-Based, Clinical Pharmacist-Led Self-Measured Blood Pressure Monitoring Program in a Federally Qualified Health Center

(6-096) Developing Pharmacist-Led Hypertension Telehealth Clinic to Improve Hypertension Management in Patients with Diabetes Mellitus at an Indian Health Service Clinic

(6-156) Controversy over Possible GLP-1 Receptor Agonist-Associated Diabetic Retinopathy

(6-157) Evidence for the Somogyi Effect: A Case Demonstrating Diagnosis and Treatment in a Patient with Type 2 Diabetes Using NPH Insulin

(6-158) Tolerable Conversions from One GLP-1 Receptor Agonist to Another Without Re-titration in Patients with Type 2 Diabetes: Two Case Reports

(6-159) Diabetes and Hearing Impairment: Knowledge, Attitudes, and Practices Among Providers and Patients

(6-191) Continuous Glucose Monitor Distribution in a Federally Qualified Health Center, Virginia Garcia Memorial Health Center

(6-192) Potential Cost-Saving Initiative with Insulin Glargine-yfgn Interchangeable Biosimilar

(6-206) Medication Affordability Discussions with Older Adults in Primary Care

(6-220) Utilization of Continuous Glucose Monitoring in Outpatient Internal Medicine for Patients with Type 2 Diabetes Mellitus

(6-222) Medication Adherence Strategies Utilized by Patients with Hypertension in Two Internal Medicine Practices

(6-223) Hemoglobin A1c Lowering and Cost Savings with Patient Assistance Programs in the Ambulatory Care Setting

(6-237) Role of a Student Pharmacist Within a Community Hospital Associated Family Health Centers’ Transitions of Care Program

(6-238) Remote Care Interventions in Type 2 Diabetes Mellitus Patients at an Urban Underserved Free Clinic During the COVID-19 Pandemic

(6-268) Description of a Pharmacist-Led Pilot Program Designed to Address Pulmonary Health Among Incarcerated Patients

(6-292) Evaluating Impact of Inhaler Training Device Education on Knowledge and Comfort Level in Prescribing Inhalers Among Family Medicine Residents

(6-297) Impact of Continuous Glucose Monitors and Pharmacist-Led Educational Interventions in Type 2 Diabetes

(7-099) Impact of Free Insulin Pump Ion Federally Qualified Health Center (FQHC) Patient Satisfaction and Diabetes Management

(7-114) Hemoglobin A1C (HbA1c) Reduction with a Pharmacist - Run Continuous Glucose Monitoring (CGM) Service in a Federally Qualified Health Center (FQHC)

(7-115) Evaluating the Relationship Between Diabetes Distress, Depression, and Anxiety on Glycemic Control in an Adult Hispanic Population

(7-116) Federally Qualified Health Center (FQHC) Continuous Glucose Monitoring (CGM) Implementation – Medication Adjustments by a Clinical Pharmacist and Their Effects on HbA1C

(7-145) Impact of Socioeconomic Factors on Patients with High Hemoglobin A1c (HbA1c) Level

(7-162) Ethnicity Differences in HbA1C Lowering with Glucagon Like Peptide – 1 Receptor Agonists Use in Type 2 Diabetes Mellitus

(7-181) Improving Access and Adherence to Parenteral Osteoporosis Therapies at a Primary Care Clinic

(7-182) Impact of Ambulatory Care APPE on Students’ Ability to Identify and Classify Medication Therapy Problems at an Academic Medical Health-System

(7-198) Prescriber Perceptions of Sulfonylurea Medications in Clinical Practice

(7-220) Return to Normal? A Longitudinal Evaluation of the Impact of COVID-19 Pandemic on Clinical Outcomes and Visit Modalities at an Urban Free Clinic

(7-231) Assessing Compounded Ketamine Prescriptions for Off-Label Use

(7-248) Impact of Medication Cost on Medication Adherence in Hemodialysis Patients

(7-264) Evaluation of Clinical Outcomes in a West Virginia Department of Family Medicine Team-Based Intensive Diabetes Clinic

(7-277) Physicians’ Perceptions of Pharmacists and Pharmacy Services at an Academic Medical Center

(7-278) Effect of Remote Monitoring and Interventions on Blood Pressure Control in Patients from a Family Medicine Clinic

(7-279) Denosumab Monitoring at an Ambulatory Endocrinology Clinic: A Retrospective Chart Review

(7-300) Effect of Tirzepatide on Glycemic Control and Weight Loss

(7-306) Evaluating a Home Blood Pressure Cuff Loaner Program in Primary Care Clinics

(7-317) Implementation of Pharmacist-Led Travel Clinic Services at UnityPoint Health-Meriter

(8-073) The Impact of an Intervention on Patients at Risk of Becoming Adherence Outliers Within an Ambulatory Care Pharmacy

(8-074) Impact of an Inflammatory Bowel Disease Pharmacist Program in an Outpatient Clinic

(8-075) Evaluating Ibandronate Prescriptions and Targeting Recommendations for Broad-spectrum Bisphosphonates (IbanBSBPs)

(8-076) Real-world Evidence on Effectiveness, Drug Persistence and Safety of Cycling Janus Kinase Inhibitors in Rheumatoid Arthritis

(8-077) Evaluation of Pharmacist Co-management of Gender Affirming Hormone Therapy in an Endocrinology Clinic (Access-GAHT)

(8-078) Role of Continuous Glucose Monitoring in the Management of Type II Diabetes Mellitus Patients: A Retrospective Review

(9-003) Identifying Causes of Therapeutic Inertia in Veterans with Uncontrolled Diabetes at a Rural Veteran Affairs Clinic

(9-004) Analysis of Factors Affecting Nonadherence to Guideline-Directed Medical Therapy in Veterans with Uncontrolled Hypertension

(9-006) Assessment of Patient Outcomes from a Pharmacist-led Interprofessional Transitions of Care Program: The ICARE Program

(9-040) Impact of a Pharmacist-Driven Continuous Glucose Monitoring Clinic on Financial and Clinical Outcomes in a Federally Qualified Health Center

(9-058) Evaluating Outcomes of a Pharmacist Led Heart Failure Collaborative Practice to Reduce Hospitalizations and Improve Quality Measures Within a Community Health Network

(9-075) Impact of a Once Weekly Glucagon-like Peptide-1 Receptor Agonist on Insulin Dose and Injection Burden in a Federally Qualified Health Center

(9-076) Long History of Hirsutism in Postmenopausal Woman with Steroid Cell Tumor of the Ovary: A Case Report

(9-083) Cross-Sectional Study of Provider Attitudes Toward Prescribing HIV Pre-Exposure Prophylaxis for Patients in a Federally Qualified Health Center

(9-084) Impact of Clinical Pharmacist Interventions on Asthma Control in a Federally Qualified Health Center

(9-094) Optimization of Lipid-Lowering Medications for Secondary Prevention of Cardiovascular Disease in Patients at Family Medicine Clinics

(9-099) Impact of Glucagon-Like Peptide 1 Receptor Agonist and Sodium Glucose Cotransporter 2 Inhibitor Combination on Glycated Hemoglobin in Outpatient Clinics of an Academic Medical Center

(9-101) Assessing the Clinical & Financial Impact of a Clinical Pharmacist-Led Inventory Management in a Large Medical Group

(9-115) Impact of a Pharmacist-Led Nirmatrelvir/ritonavir (Paxlovid) Clinic on Medication Related Outcomes and Overall Efficiency for High Risk COVID-19 Patients in an Ambulatory Care Pharmacy Setting

(9-116) Evaluation of Collaborative Strategies Between Ambulatory Care and Community Pharmacy to Improve Pharmacy-Related Star Measures and Blood Pressure for the Medicare Advantage Population

(9-117) Evaluation of the Pharmacist-Led Benzodiazepine Taper Program at Cedars-Sinai Medical Network

(9-161) Impact of a Pharmacist-driven Inhaler Clinic on Outcomes Related to COPD in a Federally Qualified Health Center

(9-169) Implementation of Pharmacy Program and Clinic to Provide Consultation on Pharmacogenetic Testing and Results

(9-170) Implementation and Evaluation of a Non-Alcoholic Fatty Liver Disease (NAFLD) Clinical Pharmacy Service Within a Hepatology Clinic

(9-189) Change of Hemoglobin A1c in Low-income Hispanic Populations Before and After Sodium-glucose Cotransporter 2 Inhibitors (SGLT2) Initiation

(9-190) Reliability of Reported Self-Monitoring of Blood Glucose (SMBG) Values Compared to Hemoglobin A1c Level and Pharmacists' Interventions in Patients with Type 2 Diabetes

(9-262) Clinical Outcomes of Anticoagulation Clinic Patients When Run by a Nurse Practitioner versus a Pharmacist

(9-265) Evaluation of the Impact of Ambulatory Care Pharmacists Within Multidisciplinary Rheumatology Clinics

(9-266) Expanding Pharmacist Collaborative Practice Agreements Across Multiple States Within a Large Academic Health System

(9-269) Evaluation of Inspiratory Flow Rate (IFR) for Patients with Chronic Pulmonary Diseases

(9-270) Optimization of an Integrated Pharmacist Collaborative Care Model in Specialty Disease State Clinics

(9-271) Real World Review of Infliximab Biosimilars at a Large Academic Health System

(9-272) Evaluation of an Ambulatory Opioid Stewardship Dashboard: Ensuring Robust Measures

(9-318) Effect of a Pharmacist-Run Clinic on Time to Disease State Management in Patients Provided with Necessary Home Monitoring Tools and Regular Follow-Up

(9-332) Evaluation of an Interdisciplinary Lipid Management Program for Treating Patients with Severe Lipid Disorders

(9-333) Avoiding Clinical Inertia: Comparing Time to Intensification of Glucagon-like peptide-1 (GLP-1) Receptor Agonists in Patients with Type 2 Diabetes Mellitus Among Clinical Pharmacists versus Providers

(9-343) Impact of an In-Office Medication Dispensing Program on Hospital Admissions and Medication Adherence

(9-378) The Role of a Transitions-of-Care Pharmacist in a Collaborative, Interdisciplinary Team

(9-398) Impact of a Pharmacist-led Transitions of Care Service on Duration of Antibiotic Therapy for Patients Receiving Treatment for Pneumonia or Urinary Tract Infection

(9-400) Economic Impact of a Pharmacist-Led Care Gap Driven Program Integrated Within a Large Healthcare System’s Primary Care Clinics Targeting a Value-Based Population

(9-406) Assess the Impact of a Pharmacist-led Value-based Diabetes Management Program Integrated Within a Large Healthcare System’s Primary Care Practice

(9-420) Evaluation of Pharmacist Involvement in Multidisciplinary Home Visits in a Primary Care Based Accountable Care Organization

(9-433) Evaluation of SGLT2 Inhibitors at an Outpatient Cardiology Clinic

(9-434) Pharmacist Impact in Preventing Emergency Department Visits and Hospital Readmissions for Heart Failure Patients in a Transitions of Care Setting

(9-442) A Retrospective Study of Patients ≥ 65 Years Old with Type 2 Diabetes Mellitus and Characteristics Associated with Sulfonylurea Utilization

(9-458) Factors and Bias in Statin Prescribing for Primary Prevention in Patients with Diabetes

(9-459) Evaluating the Efficacy of Text Messaging on Patient Outreach Rates in a Telephonic Ambulatory Care Clinic

(9-460) Pharmacist Impact on the Use of First-Line Antihypertensive Medications in the African American Population

(9-467) Evaluation of Metformin Prescribing Patterns in Patients with Type 2 Diabetes Mellitus in a Rural Healthcare Setting: Second Phase

(10-001) Effectiveness of a Type 2 Diabetes Panel Management Model Compared to a Referral-Based Model on Glycemic Control in an Ambulatory Care Setting

(10-037) The Implementation and Impact of Clinical Pharmacy Services in an Interdisciplinary Internal Medicine Clinic

(10-098) Co-Prescribing of Naloxone in the Outpatient Clinical Setting Following Implementation of a Free Take Home Naloxone Program

(10-104) Impact of a Pharmacist-Driven Medication Therapy Management Clinic on 30-Day Readmission Rate

(10-113) Justification of a Pharmacist-led Collaborative Hypertension Management Service in a Health-System Owned Primary Care Clinic

(10-124) Impact of a Pharmacy-driven Vaccination Intervention in Adult Warfarin Patients Managed in an Ambulatory Medication Management Clinic

(10-127) Efficacy of Continuous Glucose Monitoring on Glycemic Control in Adults with Type 2 Diabetes

(10-143) Evaluating the Appropriateness of Warfarin Therapy in Patients Enrolled in Anticoagulation Clinic

(10-144) Evaluation Of glycemic Control with Continuous Glucose Monitoring vs. Traditional Blood Glucose Monitoring in Patients with Type 2 Diabetes Mellitus Managed by Ambulatory Care Pharmacists

(10-148) Assessment of Gestational Diabetes Management in an Obstetrics and Gynecology Clinic for Collaborative Care

(10-150) Establishing Team-Based Weight Management Services in Primary Care Clinics

(10-152) Comparison of the Use of SGLT2i and GLP1RA in Patients with Diabetes Managed by PCP Alone vs Patients Co-managed by a Pharmacist

(10-156) Pharmacist Transitions of Care Telephonic Outreach Reduced Hospital Readmission Rates for Medicare and Medicaid Patients

(10-159) Impact of Pharmacist-Led Direct Oral Anticoagulant (DOAC) Monitoring on Appropriate Medication Use

(10-160) Comparison of Clinical Pharmacist versus Nurse Led Medicare Annual Wellness Visits in the Primary Care Clinic Setting

(10-175) Evaluation of the Frequency in Which Warfarin Was Adjusted After Nirmatrelvir/ritonavir Was Initiated in Patients Enrolled in a Pharmacist-managed Anticoagulation Clinic

(10-176) Impact of Health Literacy on Multiple Patient Variables: A Single-Center Observational Study in Lebanon

(10-199) Frequency of Direct LDL-C Measurement Follow-up in Patients with Diabetes and Elevated Triglycerides Within Ambulatory Care Clinics

(10-200) Assessment of Provider Perceptions and Knowledge of Evidence-based Obesity Treatment in the Primary Care Setting

(10-205) Frequency of Therapeutic Drug Monitoring for Narrow Therapeutic Index Drugs in Primary Care

(10-208) Impact of an Outpatient Anticoagulation Clinic on Time Within Therapeutic INR Range

(10-216) Evaluation of Achieving A1c Goals with Pharmacy Management Compared to Standard of Care

(10-227) Implementing Inclisiran in Pharmacist-Led Medication Management Clinic

(10-231) Clinical Outcomes of Incretin Mimetic Drugs Used for Weight Loss in a Pharmacist Run Clinic

(10-232) Impact of Pharmacist Involvement and Management in Patients with Diabetes That Are Enrolled in an Outpatient Endocrinology Clinic

(10-241) Use of Remote Patient Monitoring Kits to Reduce Hospitalization and Mortality Rates for Patients with Heart Failure

(10-256) Prescribing Compliance with Guideline Directed Medical Therapy for American College of Cardiology/AHA Heart Failure Guidelines

(10-261) Impact of Pharmacist-Managed Diabetes Medication at a Chronic Care Clinic in a Rural Community

(10-262) Comparison of Pharmacist versus Other Health Care Provider’s Nirmatrelvir/Ritonavir Prescribing Habits in a Rural Health Care System

(10-278) Impact of a Clinical Pharmacist on the Prevention and Management of Diabetic Kidney Disease in an Ambulatory Care Setting

(10-290) Evaluation of Clinical Inertia in Patients Living with Type 2 Diabetes Within a Federally Qualified Health Center

(10-320) The Effects of Pharmacy Involvement on HbA1C in Overbasalized Patients with Type 2 Diabetes Mellitus at a Federally Qualified Health Center

(10-329) Impact of Pharmacist-led Intervention on Improving Health Outcomes in Patients with Diabetes

(10-330) Impact of Pharmacy-Driven Transitions of Care on 30-day Hospital Readmission

(10-332) Impact of Pharmacist-led Interventions on Polypharmacy Amongst Elderly Patients in the Ambulatory Care Setting

(10-341) Re-evaluation of Prescribed Warfarin and Aspirin Combination Therapy in a Community Hospital Anticoagulation Clinic

(10-360) Implementation of a Clinical Pharmacy Service to Improve Adherence to Guidelines for Combined Hormonal Contraception Prescribing in Women with Hypertension

(10-372) Impact of a Multidisciplinary Approach Towards Nirmatrelvir-Ritonavir Treatment on COVID-19 Related Hospitalization Rates at a Federally Qualified Health Center

(10-373) Clinical Impact of Empagliflozin on eGFR in Patients at a Federally Qualified Health Center with a Predominant Hispanic Patient Population

(10-377) Impact of American Diabetes Association 2022 Guidelines on Prescribing Rates of Sodium Glucose Cotransporter-2 Inhibitors in Ambulatory Care Organization Patients with Type 2 Diabetes

(10-395) Utilization and Effectiveness of Angiotensin Receptor-Neprilysin Inhibitors (ARNI) and Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients with Heart Failure

(10-413) Pharmacist-provided Educational Intervention and Its Impact on Medical Resident Knowledge and Comfort Level with Continuous Glucose Monitors (CGMs)

(10-460) Quality Assessment of Parenteral Osteoporosis Medication Monitoring and Follow-up in the Ambulatory Setting

(11-012) In-Check DIAL Training: Impact on Inhaler Utilization in a Pharmacist Led Asthma & COPD Clinic

(11-021) Evaluation of Buprenorphine Use Before and After COVID-19 at CentraCare Family Health Clinic

(11-022) Pharmacist Clinician-Led Opioid Tapers: Observations of a Collaborative Practice Agreement

(11-023) Effect of Pharmacist-Led Discharge Delivery and Medication Therapy Management Services on Unscheduled 30-day Readmission Rates

(11-051) Use of Continuous Glucose Monitors in Patients with Type 2 Diabetes Who Are Newly Insulin-Dependent

(11-053) Long-Term Outcomes with Elexacaftor/Tezacaftor/Ivacaftor in Pediatric Patients with Cystic Fibrosis

(11-073) Survey of Self-Identified Prescriber Tendencies Regarding Sodium-Glucose Cotransporter-2 Inhibitor Outpatient Prescribing at a Large Community Health System

(11-091) Impact of a Pharmacist Post-Discharge Transitions of Care Workup on 30-day Readmissions and Other Quality Health Metrics

(11-118) Assessing the Impact of Pharmacist-led Digital Retina Scan Services on Rates of Annual Eye Exams for Patients with Diabetes at a Federally Qualified Health Center

(11-124) Bad to the Bone: Evaluation of Osteoporosis Management at a Community Teaching Health System

(11-130) Implementation of a Pharmacist-Led Weight Management Program with Remote Monitoring in Patients with Obesity Compared to the Standard of Care with Primary Care Provider Management

(11-164) Standardizing a Patient Disenrollment Process from the Pharmacist Run Diabetes Service at Dartmouth Health Clinics

(11-165) Identification of Outpatients Eligible for Proton Pump Inhibitor De-Prescribing to Support Generation of a Collaborative Practice Agreement in the Geriatric Population

(11-169) Implementation of the BOOST (Better Outcomes by Optimizing Safe Transitions) Tool Within a Community Hospital’s Meds-to-beds Program: Analysis of Workflow and Quality Outcomes

(11-201) Aspirin(g) to Improve Low-dose Aspirin Prescribing for Primary Prevention

(11-202) Evaluation of the Appropriateness of DOAC Prescribing in the Primary Care Setting

(11-233) Optimization of Pharmacotherapy to Improve Renal Outcomes in Patients with Diabetes and Chronic Kidney Disease Receiving Care at a Community Clinic

(11-238) Identifying Barriers to Effective Glycemic Control in Type 2 Diabetics with Hemoglobin A1C ≥8% and Implementing Pharmacist-led Interventions to Optimize Disease Management and Patient Outcomes

(11-255) Chronic Obstructive Pulmonary Disease Management in an Integrated Healthcare System: A Process Improvement Project

(11-259) Assessment of Atherosclerotic Cardiovascular Disease (ASCVD) Risk and Statin Utilization in Patients at Community Pharmacies

(11-261) Evaluation of Continuity of Care with Infliximab Biosimilars

(11-273) Impact of Biologics on Inner-City Patients with Severe Persistent Asthma in an Outpatient Pulmonary Clinic

(11-284) Impact of Pharmacist Intervention During Transitions of Care Within an Ambulatory Care Practice

(11-285) Establishment of a Postgraduate Year 2 (PGY2) Ambulatory Care Pharmacist Resident Service at a Federally Qualified Healthcare Center (FQHC) in an Urban Setting

(11-308) Implementation of a Collaborative Pre-exposure Prophylaxis Service: Evaluation of Acquiring HIV - A Retrospective Study

(11-339) Weight Loss Associated with Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Use in Real World Settings in Niagara Falls, NY

(11-367) Evaluation of Clinical Preventive Services in a Pharmacist-Run Ambulatory Care Clinic Providing Care to an Underserved Patient Population in Brooklyn, NY

(11-368) Evaluation of Glycemic Control in Patients with Uncontrolled Type II Diabetes Provided with a CGM Device versus non-CGM Based Diabetic Care

(11-372) Evaluation of Ambulatory Care Interventions on Diabetes Outcomes in a Disparate Urban Community

(11-374) Assessing the Impact of Pharmacist Counseling on Decreasing 30- day Readmission Rate Due to Incidence of Diabetic Ketoacidosis and Uncontrolled Hyperglycemia

(11-389) Medicaid & Medicare Coverage of Anti-Obesity Medications: An Analysis of Approvals for Medications Indicated for Weight Management

(11-390) Impact of Sodium-Glucose Cotransporter-2 Inhibitors on the Incidence of Urinary Tract and Genital Infections in a Geriatric Patient Population with Type 2 Diabetes

(11-396) Evaluation of Outpatient Antibiotic Prescribing for Skin and Soft Tissue Infections

(11-398) Effects of Continuous Glucose Monitoring (CGM) on Glycemic Control in Adults with Type 2 Diabetes (T2DM)

(12-001) Evaluation of Heart Failure Quality and Safety Metrics of a Clinical Pharmacist Practitioner-Led Ambulatory Care Medication Management Program

(12-035) Impact of Telephone-Based Pharmacist-Led Smoking Cessation Service in Pulmonology Clinic

(12-040) Impact of Pharmacist Targeted Interventions in the Management of Hypertriglyceridemia in Patients with Type-2 Diabetes at High Risk for Cardiovascular Events

(12-050) Evaluation of Prescribing and Monitoring Practices for Direct Oral Anticoagulants (DOACs) by Providers and Outpatient Clinics

(12-051) Assessment of Pharmacist-Physician Covisit Model Sustainability in a Rural Health Clinic

(12-052) Assessment of DOAC Prescribing at Discharge from a Community Teaching Hospital

(12-060) Pharmacist Intervention in Heart Failure Patients with Moderate to High Risk of 30-day Readmissions Using ToPP-HF Tool

(12-061) The Rate of Outpatient Follow-up Among Recently Hospitalized Heart Failure Patients

(12-062) Review of Glucagon-like Peptide-1 Receptor Agonists Used in Prediabetes and the Effects on Hemoglobin A1c

(12-063) Impact of Pharmacist Recommendations on a Shared Savings Model

(12-076) Safety and Efficacy of Weight Loss Medications

(12-077) Evaluation of Insulin Pump Therapy in Patients with Type 1 or Type 2 Diabetes Previously on One or More Daily Insulin Injections

(12-083) Evaluation of Appropriate Dual Antiplatelet Therapy Use and Duration

(12-102) Assessing the Risk of Lower Limb Amputations in Patients Using Sodium-glucose cotransport-2 Inhibitors with Type 2 Diabetes Mellitus and Peripheral Vascular Disease

(12-124) Evaluation of Diabetes Mellitus Clinical Outcomes for Patients Enrolled in a Pharmacist Led Continuous Glucose Monitor Program Within Two Family Medicine Offices

(12-131) Effect of Extended Pharmacist Involvement in Discharge Transitions of Care on Hospital Readmission Rates

(12-144) Evaluation of the Impact of Pharmacists' Intervention on Hemoglobin A1C for Employee Diabetic Program in Southern Ohio

(12-145) Interdisciplinary Collaboration Between Pharmacists and Other Providers for Patients with Recently Started or Altered Doses of Antidepressants And/or Antipsychotics

(12-160) Ambulatory Care Pharmacist Credentialing and Privileging Process Within a Medication Management Setting

(12-176) Assessing Physician Adherence to the Use of Controlled Substance Agreements for Patients on Chronic Schedule II Controlled Substances at an Internal Medicine/pediatrics Resident Teaching Clinic

(12-182) Conducting Pharmacist-led Medicare Annual Wellness Visits in a Federally Qualified Health Center

(12-184) Assessing the Impact of a Pharmacist-driven Remote Patient Monitoring Program Utilizing Smart Devices on Adult Patients with Hypertension or Diabetes Within a Rural Health Program

(12-195) Glucagon-Like Peptide 1 Receptor Agonists: Safety and Efficacy Differences in a Real-World Population

(12-200) Retrospective Review of Deprescribing Trends After Initiation of SGLT2 Inhibitors to Account for Known Physiologic Effects

(12-202) Evaluating the Impact of Pharmacist-Led Visits for Medicare Part D Beneficiaries

(12-203) Project DAWN (Deaths Avoided with Naloxone): A Review of the University Hospitals Naloxone Distribution Program

(12-206) Evaluation of Statin Initiation and Utilization in Diabetic Patients at University Hospitals

(12-222) Assessing the Impact of a Pharmacy-based Workflow to Address Adherence Barriers in Ambulatory Patients

(12-232) Assessing Current Knowledge of Hearing Impairment with Diabetes in Providers with CDCES Certification

(12-248) Identifying Ideal Candidates for GLP-1 Receptor Agonists to Optimize Cost-Effective Prescribing Strategies for Type II Diabetes Within a Managed Care Organization

(12-255) Examination of Patient Outcomes from Clinical Pharmacist-led Telehealth Services Surrounding the COVID-19 Pandemic

(12-265) Adherence to Recommended Laboratory Monitoring Following Initiation of Teriflunomide in Patients with Multiple Sclerosis (MS)

(12-294) Appropriateness of Angiotensin Converting Enzyme Inhibitors (ACE) and Angiotensin Receptor Blockers (ARB) Utilization in Presence of Albuminuria

(12-311) Prevalence of Appropriate Medication Therapy Selection and Monitoring for Chronic Gout Managed by Primary Care

(12-333) Evaluation of Pharmacist Interventions for Oral Anticancer Therapies at an Ambulatory Medication Management Clinic

(12-345) Diuretic Adjustments Following the Initiation of SGLT2 Inhibitor Therapy for Heart Failure

(12-359) Evaluation of Glycemic Control Following GLP-1 Receptor Agonist Interchange in an Outpatient Clinic

(12-360) Evaluation of a Pharmacist-managed Diabetes Clinic in a Family Medicine Clinic

(12-383) Implementing a Pharmacist E-Consult Service in a Large Urban Family Health Center

(12-398) Incidence of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Prescribing in Patients Diagnosed with Diabetes Mellitus and Microalbuminuria in a Chronic Disease State Management Clinic

(12-399) Evaluation of Dietary Supplement Use and Drug Interactions in an Outpatient Medication Management Clinic

(12-415) Impact and Utilization of 340b Prescribing Among Ambulatory Care Pharmacists

(12-418) Implementation of a Hybrid Virtual Medication Management Program Within an Employer-Based Patient Centered Medical Home

(12-419) Direct Oral Anticoagulant Dosing Appropriateness in Primary Care and Outpatient Cardiology Clinics

(13-067) Evaluation of Primary Care Providers’ Utilization of Glucagon-Like Peptide 1 Receptor Agonists with Demonstrated ASCVD Benefit in Patients with Type II Diabetes Mellitus

(13-080) Impact of Pharmacist Involvement in a Multidisciplinary Amyotrophic Lateral Sclerosis (ALS) Clinic

(13-081) Evaluation of Hypoglycemia Incidence in Patients Achieving Target Hemoglobin A1c Receiving Traditional Antidiabetic Agents versus Novel Therapies

(13-169) Development of a Rheumatology Clinical Pharmacy Service at an Academic Health Center

(13-170) Assessment of Compliance with National Standards for Metabolic Monitoring of Second-Generation Antipsychotics at a Standalone Behavioral Health Clinic Within a Large Academic Health System

(13-171) Evaluation of Sodium-Glucose Cotransporter 2 Inhibitor Use in Heart Failure Patients at an Academic Institution

(13-172) Development of an Ambulatory Pulmonology Pharmacotherapy Consult Service (APCCS) at an Academic Health Center

(13-187) Effect of a Pharmacist-led, Collaborative Practice on Clinical Outcomes in Persons with Diabetes

(13-210) CUIDAR: COVID-19 and Understanding the Impact on Diabetes Patients’ Attitudes and Medication Requirements

(13-293) Integrated Oncology Pharmacist Pilot

(13-304) Implementation of a Pharmacist-Led HIV Oral PrEP (Pre-Exposure Prophylaxis) Management Pathway at an Academic Internal Medicine Practice

(13-305) Effect of Removing Race Coefficient from Glomerular Filtration Rate Estimating Equation on SGLT2 Inhibitors Eligibility

(13-321) Clinical Outcomes Associated with Pharmacist Intervention in the Management of Iron Deficiency Anemia in Heart Failure Patients

(13-322) Deprescribing Protocol for Intranasal Corticosteroids and Proton Pump Inhibitors for Adult Patients with Cystic Fibrosis

(13-325) Bridging the Gap: Reducing Readmission Rates with Post-Discharge Follow-Up

(13-326) Evaluation of Urogyn Infections with Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor Usage; A Comparison Between Real World Incidence and Literature

(13-329) Establishing a Tobacco Wellness Program for Hospital Employees

(13-335) Clinical Pharmacist Impact on Optimizing Patient Outcomes in Individuals Receiving Oral Chemotherapy Agents in an Ambulatory Care Setting

(13-338) Integration of a Clinical Pharmacist for HIV Management in an Internal Medicine Teaching Clinic

(13-339) The Impact of a Clinical Pharmacist on Diabetes Bundle Metrics in a Primary Care Clinic

(13-343) Evaluating the Impact of Pharmacist-led Asthma Management in an Ambulatory Care Clinic

(13-344) Establishment of a Pharmacist-led Ambulatory Care Service to Improve Access in Human Immunodeficiency Virus Pre-exposure Prophylaxis Administration

(13-353) Initiation and Optimization of a Collaborative Migraine Pharmacotherapy Service

(13-354) Initiation of a Collaborative, Pharmacist-Driven Pharmacotherapy Pulmonary Service in the Ambulatory Care Setting

(13-358) Optimization of Patient Outcomes in a Pharmacist-Led Osteoporosis Pharmaceutical Care Clinic

(13-362) Implementation of Pharmacy Service in a Primary Care Clinic to Improve Antidepressant Persistence

(13-364) Assessing and Optimizing the Workflow of Pharmacist-led Tacrolimus Monitoring in the Nephrology Clinic Setting

(13-381) Evaluation of the Effect of Metabolic Syndrome in the Cause of Breast Cancer in a Minority Population - Data Analysis on Patients in Ambulatory Clinics

(13-399) Evaluation of the Prescribing Habits of COVID-19 Guideline-Directed Treatments in a Primary Care Walk-In Clinic

(13-404) Impact of Ambulatory Care Pharmacists on the Management of Patients with Uncontrolled Type 2 Diabetes Mellitus

(13-409) Impact of a Pharmacist-Led Continuous Glucose Monitoring (CGM) Clinic on Glycemic Control in Patients with Type 2 Diabetes

(13-416) Evaluation of Direct Oral Anticoagulants (DOAC) and Potential Inconsistencies with Recommended Dosing in Ambulatory Patients in a Community Hospital Health System

(13-431) Impact of a Pharmacist Led Comprehensive Medication Management Review in Patients with Diabetes in a Rural Healthcare Setting

(13-432) Implementation of Pharmacist-driven Review of Medications Associated with Increased Fall Risk for Patients with or at an Increased Risk of Osteoporosis

(13-438) Optimizing Workflow for Referral to Interdisciplinary Transitions of Care Service Following Hospital Discharge

(13-439) Reduction of Loop Diuretics When Combining with Sodium Glucose Cotransporter 2 Inhibitors

(13-444) Creation and Implementation of a Pharmacist-led Aspirin Deprescribing Protocol for Patients Inappropriately on Aspirin for ASCVD Primary Prevention

(13-453) Naloxone Access at a Family Medicine Clinic---Associated Community Pharmacy

(13-454) Creation and Implementation of a Pharmacist-Created HIV PrEP Clinic at Health Care for the Homeless Clinic

(1-008) Impact of Population Management Utilization on Heart Failure Outcomes in a High-Risk Veteran Population

(1-010) Medication Use Evaluation of Sacubitril/Valsartan in a Veterans Affairs Health Care System

(1-017) Pharmacist-Driven Identification and De-escalation of Unnecessary Aspirin Therapy in Elderly Adults on Concomitant Direct Oral Anticoagulants

(1-028) Impact of Pharmacists on Uptake of SGLT2i Prescribing for HFrEF

(1-043) Increasing Implementation of Guideline Directed Medical Therapy for Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure Patients with Reduced Ejection Fraction

(1-046) Implementation of Pharmacist-Led Congestive Heart Failure Discharge Education

(1-054) Evaluating the Prevalence of Osteopenia or Osteoporosis in Veterans on Long-Term Warfarin Therapy at VA Sierra Nevada Health Care System Anticoagulation Clinic

(1-065) Multi-Factorial Analysis of Gastrointestinal Bleeding Risk and Events in Veteran Patients on Combination Antiplatelet-Anticoagulant Therapy

(1-078) Assessing Bleeding Risk Mitigation in Patients Receiving Combination Antithrombotic Therapy: A Study on Blood Pressure Control and Prescribing Patterns

(1-095) Minimizing the Use of High-risk Medications in Veterans with Heart Failure: A Pharmacy-Led Quality Improvement Project

(1-114) Effectiveness of Pharmacist-driven Thromboprophylaxis Screening Utilizing the Khorana Score

(1-126) Correlation Between Anticoagulant Treatment Options and Incidence of Venous Thromboembolism in the Setting of Moderate to Severe COVID-19 Infections

(1-129) Safety of Venous Thromboembolism Prophylaxis in Underweight Hospitalized Veteran Patients

(1-143) Evaluating the Effects of Implementing a Dashboard in Monitoring Direct Oral Anticoagulants in Appropriate Prescribing Patterns

(1-170) Evaluation of Anticoagulation Reversal Management in a Veterans Affairs Health Care System

(1-176) Analysis of the Decision Support Order Set for Direct Oral Anticoagulants at the Veterans Affairs Southern Nevada Healthcare System

(1-207) Evaluating Guideline Directed Heart Failure Medication Therapy Prescribing Practices in Recently Hospitalized Patients at Northport Veteran’s Affairs Medical Center (VAMC)

(1-220) Identifying Discrepancies and Standardizing Antiarrhythmic Monitoring

(1-238) Evaluation of Pulmonary Artery (PA) Pressure Implanted Remote Monitoring HF System in Patients with Heart Failure

(1-244) Apalutamide-Warfarin Interaction: A Case Report

(1-249) Safety Evaluation of Low Dose Rivaroxaban Plus Clopidogrel for Treatment of Peripheral Arterial Disease at Corporal Michael J. Crescenz VA Medical Center

(1-274) Comparison of Bleeding Rates Between Rivaroxaban and Apixaban Among NSAID Users versus Non-NSAID Users

(1-277) Risk of Acute Kidney Injury After Addition of Empagliflozin and Dosing Changes to Background Congestive Heart Failure Therapy in a Veteran Population

(1-279) Significance of the Loading Phase Duration of Apixaban on Bleeding Events in Patients Treated for Newly Diagnosed Venous Thromboembolism After Initial Parenteral Anticoagulation Treatment

(1-280) Impact of Race and Weight on Heart Failure Admissions in Veterans on Sacubitril/Valsartan

(1-286) Pharmacist-Led Initiative to Improve Glycemic Control Therapies in Veterans

(1-289) Outcomes Associated with Single Anti-Platelet Therapy Combined with an Anticoagulant in Patients Undergoing Percutaneous Coronary Intervention with Pre-Existing or New-Onset Atrial Fibrillation

(1-308) Pharmacist Optimization of Guideline-Directed Medication Therapy (GDMT) in Heart Failure

(1-330) Implementing a Revision in Anticoagulation Consult for Patients on Warfarin Being Discharged

(1-338) Unfractionated Heparin Monitoring: Transitioning from aPTT to anti-Xa at the Cheyenne VA Health Care System

(1-345) Implementation of Clinical Pharmacy Services for Initiating SGLT-2 Inhibitors in Hfref Patients on Guideline Directed Medical Therapy

(2-025) Comparing the Effects of Heparin Infusion Maximum Dose Limits in Morbidly Obese Patients to Weight-based Dosing in Non-obese Patients

(2-040) Evaluation of Provider Awareness and Understanding of Stroke Risk and Anticoagulation Therapy in Patients with Non-Valvular Atrial Fibrillation

(2-041) Effectiveness and Safety of Transitions from Parenteral Anticoagulation to Rivaroxaban or Apixaban for Venous Thromboembolism Treatment

(2-079) Appropriateness of Direct Oral Anticoagulants Dosing in Patients with Nonvalvular Atrial Fibrillation Managed by an Interdisciplinary Team

(2-085) Ivabradine Therapy Appropriateness and Its Implications for Heart Failure Patients

(2-093) Acute Effects of Enhanced External Counterpulsation (EECP) on Cardiac Output

(2-103) Outcome of Enoxaparin Bridging in Left Ventricular Assist Devices in an Ambulatory Care Setting

(2-108) Alteplase versus Tenecteplase for Acute Ischemic Stroke: A Retrospective Cohort Analysis

(2-125) Evaluation of an Institutional Anticoagulant Thromboprophylaxis Protocol for Hospitalized Patients Infected with the COVID-19 Delta or Omicron Variants

(2-135) Potential Risk of Direct Oral Anticoagulant Use in Patients with Inflammatory Bowel Disease

(2-136) Characteristics of a Safety Net Population with Uncontrolled Hypertension: A Cross-Sectional Analysis

(2-143) Treatment of Babesiosis in a Patient with Complex Cardiovascular History and Chronically Elevated QTc: Azithromycin Plus Atovaquone

(2-144) The Impact of Berberine Alone vs. Control on Lipoprotein Concentrations in Patients with Hyperlipidemia: A Systematic Review and Meta-Analysis

(2-145) Impact of Berberine-Containing Products versus Active Drug or Dietary Therapy on Lipoprotein Concentrations in Patients with Hyperlipidemia: A Systematic Review and Meta-Analysis

(2-162) Time to Goal: Evaluation of Heparin Infusion Protocols at a Newly Opened Acute Care Hospital

(2-168) Initiation of Dofetilide Following Rapid Transition from Amiodarone

(2-188) Evaluating the Role of Factor XI(a) Inhibition in Preventing Venous Thromboembolisms

(2-199) Assessment of Provider Knowledge and Therapeutic Approaches for Reducing Stroke Risk in Patients with Nonvalvular Atrial Fibrillation

(2-221) Evaluation of Anticoagulation Administration Post Cardiac Ablation in Patients with Atrial Fibrillation

(2-222) Comparison of Heparin Nomograms on Time to Therapeutic Partial Thromboplastin Time (PTT)

(2-223) Association of Genetic Polymorphisms and Loop Diuretic Interactions with Survival in Patients with Heart Failure

(2-224) Determining the Effect of Bivalirudin on INR Levels in Hospitalized Patients Receiving Warfarin Bridging Therapy

(2-244) Effects of a System Implemented Anticoagulation Management Protocol for Impella CP Patients

(2-276) Risk-Benefit Analysis of a Patient with Ehlers-Danlos Syndrome Presenting with Hemostatic Abnormalities

(2-295) Milrinone Compared with Dobutamine on Impella Support Duration in Patients with Cardiogenic Shock

(2-303) Assessing Interventions After Identification of Prolonged Corrected QT Intervals

(2-304) Comparing Characteristics Among Black Heart Failure with Reduced Ejection Fraction (HFrEF) Patients Based on Renin-Angiotensin System (RAS) Inhibitor Use at a Veterans Affairs Medical Center

(3-006) Comparison of Furosemide Prescribing and Heart Failure Hospitalizations by State from 2017 to 2019

(3-091) Enhanced Recovery After Surgery (ERAS): Multimodal Pain Regimen in Heart Transplant and Left Ventricular Assist Device Surgery

(3-096) Assessing Anticoagulation Management in Patients on Concomitant Rifampin

(3-103) Evaluation of Post-Surgical Discharge Amiodarone Monitoring and Toxicities at a Cardiac Care Center in the United Kingdom

(3-104) Adherence to Secondary Preventative Medications Following Acute Myocardial Infarction

(3-138) Evaluation of Heparin Line Labeling After Implementation of Process Improvement Initiatives

(3-139) Medication Use Evaluation of a Therapeutic Enoxaparin Collaborative Practice Monitoring Protocol

(3-197) Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants (DOACs) versus Warfarin in Obese and Morbidly Obese African American (AA) Patients

(3-228) Selecting a Glucagon-Like Peptide- 1 Receptor Agonist versus Sodium-Glucose Co-Transporter-2 Inhibitor for Secondary Prevention of Major Cardiovascular Events Post-Stroke

(3-238) Prophylactic Amiodarone Use in the Management of Postoperative Atrial Fibrillation at Luminis Health Anne Arundel Medical Center

(3-248) Enoxaparin Anti-Xa Monitoring in Obese Patients with Acute Venous Thromboembolism

(3-249) Systematic Review and Bayesian Network Meta-analysis of Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors on Cardiovascular Outcomes

(3-293) Efficacy of a Digoxin Load Order Panel for Atrial Fibrillation or Flutter with Rapid Ventricular Response

(3-303) Impact of Polypharmacy on Time in Therapeutic Range for Older Adults with Atrial Fibrillation Taking Warfarin

(3-304) Evaluation of the Safety of Inpatient Utilization of Empagliflozin

(3-308) Optimizing Heart Failure Guideline Directed Medical Therapy Utilization by Enhancing Transitions of Care

(4-011) Patients Who Require Invasive Procedures While Receiving P2Y12 Inhibitors Incur Greater Healthcare Resource Utilization and Costs

(4-012) Metoprolol and CYP2D6: A Retrospective Cohort Study Evaluating Genotype-based Outcomes

(4-013) Evaluation of Direct Oral Anticoagulant Use Following Surgical Bioprosthetic Valve Replacement

(5-006) Retrospective Chart Review Comparing Safety and Efficacy of Direct Oral Anticoagulants versus Warfarin in Patients Diagnosed with Liver Impairment

(5-010) Differences in the Approach to Guideline Directed Medical Therapy in Patients with Heart Failure with Reduced Ejection Fraction: A Survey of Cardiologists, Internists, and Pharmacists

(5-028) Ticagrelor-Induced Syncope in Bradycardic Patient

(5-043) Impact of Pharmacist-Driven Messaging to Improve Guideline Directed Medical Therapy (GDMT) in Heart Failure with Reduced Ejection Fraction (HFrEF) Patients

(5-051) Impact of a Student Pharmacist Led Medication Counseling Program for Patients with Heart Failure in a Community Hospital

(5-098) Assessment of the Implementation of a Heparin Bolus Nomogram for Percutaneous Coronary Intervention to Improve Time to Goal Activated Clotting Time: A Subgroup Analysis

(5-150) SGLT-2 Inhibitors Impact on Hospital Readmission Rates and Length of Stay in Heart Failure Patients

(5-152) Evaluating Direct Oral Anticoagulant Appropriateness at a Community Hospital: A Retrospective Analysis

(5-180) Impact of a Pharmacist Driven Weight Loss Service in Evaluating Tolerability and Efficacy with Glucagon-like Peptide-1 (GLP-1) Receptor Agonists

(5-194) Appropriateness of Apixaban Dosing Before and After Implementation of Order Set in an Inpatient Setting at Community Teaching Hospital

(5-207) Comparison of Standard Dose versus Reduced Dose Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease Receiving Hemodialysis

(5-232) The Effects of Major Modifiable Risk Factors on Blood Pressure Levels in US Adults Not Taking Antihypertensive Therapy

(5-233) Trends in Antihypertensive Medication Use and Blood Pressure Control Among United States Adults with Hypertension, the National Health and Nutrition Examination Survey, 2001 to 2020

(5-141) A Retrospective Evaluation of Perioperative Anticoagulation Management at a Community Hospital

(5-248) Evaluation of Time to Therapeutic Activated Partial Thromboplastin Time in Patients on Unfractionated Heparin Infusion Among Different Weight Categories

(5-249) Compliance with Activated Partial Thromboplastin Time (aPTT) Monitoring and Heparin Infusion Dosing Adjustments as Part of a Hospital Dosing Nomogram in Adults

(5-271) Risk Assessment of Patients Treated with and Without Therapeutic Anticoagulation for Atrial Fibrillation in the Intensive Care Unit

(5-272) Impact of Pre-Operative P2Y12 Platelet Reactivity Units on Peri- and Post-Operative Bleeding Events in Cardiac Surgery Patients

(5-273) Evaluation of Ivabradine Utilization Within a Western New York Health System

(5-284) Evaluation of Treatment Approaches for Chronic Deep Vein Thrombosis (DVT)

(6-024) Evaluation of Weight-Based Heparin Protocol and Time to Therapeutic Range

(6-028) Evaluation of Aspirin Use in Primary Prevention Patients 60-69 Years of Age

(6-029) Utilization of Direct-acting Oral Anticoagulants for Heparin-Induced Thrombocytopenia

(6-046) Full versus Abbreviated Loading Durations of Apixaban and Rivaroxaban After Initial Parenteral Anticoagulation in the Treatment of Venous Thromboembolism

(6-122) INR Management in Antiphospholipid Syndrome Patient with Type II Secondary Arteriovenous Fistula

(6-123) Clinical Impact of Compounded Heparin Preparations at the Johns Hopkins Health System

(6-161) Guideline-Directed Medical Therapy Following Cardiogenic Shock

(6-166) Evaluation of Socio-demographic Influences on the Prescribing of Heart Failure Guideline Directed Medication Therapies (GDMT)

(6-167) Analysis on the Impact of Adding a Clinical Pharmacist to the OHSU Heart Failure Clinic on Prescribing and Adherence to Guideline-Directed Medical Therapy (GDMT)

(6-172) Warfarin Sensitivity in Decompensated Heart Failure

(6-175) Initiation and Optimization of the Four Pillars of Survival in Heart Failure with Reduced Ejection Fraction

(6-193) Assessment of Free-trial Card Usage with Sodium-glucose co-transporter-2 Inhibitors for Heart Failure Patients upon Inpatient Discharge to the Outpatient Setting

(6-194) Impact of Dofetilide Initiation Dosing Policy on First Dose Order

(6-212) Evaluation of Unfractionated Heparin (UFH) in the Treatment of Venous Thromboembolism (VTE) and Atrial Fibrillation (AF) Utilizing Dose Capping at a Large Academic Medical Center

(6-239) Effectiveness of Standard- versus Intermediate-Dose Prophylactic Anticoagulation in Hospitalized COVID-19 Patients

(6-240) Safety of Standard- versus Intermediate-dose Prophylactic Anticoagulation in Hospitalized COVID-19 Patients

(6-245) The Impact of Outpatient versus Inpatient Initiation of Sodium Glucose Cotransporter-2 Inhibitors on Heart Failure with Reduced Ejection Fraction Hospitalization and All-Cause Death

(6-246) Development of a Systematic Review on Primary Care Screening for Cardiovascular Disease Risk Factors in Sub-Saharan Africa

(6-247) Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Outcomes in Patients with Heart Failure Using Real-World Evidence

(6-269) Evaluation of Anticoagulation Practices in Patients with a Percutaneous Left Ventricular Support Device

(6-270) Appropriateness of Aspirin Based on Updated Cardiovascular Guidelines for Program of All-Inclusive Care for the Elderly of Rhode Island (PACE-RI) Patients

(6-281) Evaluation of Specialized Heparin Infusion Protocols for Neuroscience and DOAC Patients at a Large, Tertiary Medical Center

(6-298) Characteristics of Heart Failure Patients Readmitted for Intravenous Diuretic Administration

(6-304) Assessing Provider Knowledge of Atrial Fibrillation to Determine Barriers to Care in an Outpatient Cardiology Clinic

(7-012) Evaluation of Low Dose Apixaban Post-discharge for Thromboembolism Prophylaxis for Patients Enrolled in Covid to Home Program

(7-014) Rate This! Atrial Fibrillation Rate Control with Digoxin in Cardiac Amyloid

(7-025) Case Series Report of Dofetilide for Implantable Cardioverter-Defibrillator (ICD) Shock Prevention

(7-027) Evaluation of Intravenous Antibiotic Sodium Content and Outcomes in Patients with Acute Decompensated Heart Failure

(7-028) Evaluation of Heparin-Induced Thrombocytopenia Antibody Tests and Serotonin Release Assays

(7-036) Development of Eosinophilic Myocarditis in a Patient with a History of Asthma

(7-048) Assessment of Prescribing Patterns and Patient Disposition from the Emergency Department for Newly Diagnosed Deep Vein Thrombosis

(7-072) Risk Evaluation and Anticoagulation Quality Assessment in Atrial Fibrillation

(7-117) Describing the Association Between Oral FXaI-Specific Anti-Xa Concentrations and Heparin Anti-Xa Activity

(7-118) Efficacy and Safety of Aspirin and P2Y12 Inhibitors as Single Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Systematic Review

(7-144) Clinical Outcomes of Coenzyme Q10 Use Prior to Coronary Artery Bypass Graft

(7-154) Decreased Enoxaparin Anti-factor Xa Activity Levels in a Pregnant Female After Therapeutic Plasma Exchange: A Case Report

(7-163) Use of Empagliflozin in a Patient with a History of Dapagliflozin-Associated Hypersensitivity

(7-164) Retrospective Cohort Study to Compare the Efficacy of Metoprolol Succinate Given Once Daily versus Twice Daily in Patients with Atrial Fibrillation

(7-183) Treatment Pathways and Outcomes in Superficial Vein Thrombosis: A Descriptive Study (TOST)

(7-184) Standardizing the Antiplatelet Approach for Patients in the Setting of Percutaneous Coronary Intervention (PCI): A Quality Improvement Project

(7-200) Clinical Implication Score and Cost-effective Analysis of Pharmacogenetics-based Antiplatelet Treatment

(7-211) An Assessment of Pharmacotherapy for Patients with Previous Cardiac Events or Atherosclerotic Coronary Vascular Disease: A Retrospective Chart Review

(7-214) The Effect of Anticoagulant Selection and Dose on Bleeding and Thrombotic Events in COVID-19 Patients

(7-226) Inpatient Anticoagulation Services at University of Washington Medical Center: Are Standards of Practice Being Met After Transition to EPIC?

(7-227) Review of Heparin Dosing for Patients with an Impella Device

(6-165) A Retrospective Review of Therapeutic Enoxaparin Dosing and Anti-Xa Level Monitoring in Obesity

(7-280) Evaluation of Intravenous Ferric Gluconate Replacement for Hospitalized Adult Patients

(7-281) Evaluation of Appropriate Dosing upon Initiation of Sacubitril-valsartan in an Acute Care Setting

(7-318) Utility of Therapeutic Drug Monitoring for Prophylactic Enoxaparin in Trauma, Burn, and Intensive Care Patients

(8-038) Utilization of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients Admitted for Acute Heart Failure Exacerbation

(8-064) Evaluation of Clinical Decision Support to Improve Care for Patients with Atrial Fibrillation at Increased Stroke Risk: 2-Year Results

(8-079) Role of Dopamine D2 Receptor Agonist Prolactin Inhibitor Bromocriptine in Management of Cardiogenic Shock Developed During Childbirth Secondary to Acute Peripartum Cardiomyopathy (PPCM). Case Report

(8-080) Evaluation of a Hybrid Human-electronic Data Collection Process for Determining Alignment of Periprocedural Anticoagulation Practices at a Rural Medical Center: A Retrospective Quality Improvement Study

(8-081) Evaluation of High Dose Recombinant Factor Viia for Perioperative Bleeding in Cardiac Surgery Patients

(9-001) Medication Use Evaluation of Cangrelor

(9-015) Evaluation of Pharmacist-directed Heparin Infusion Management

(9-018) Evaluating the Implementation of Pharmacist-Driven Enoxaparin Dosing Protocols and Anti-Xa Level Monitoring

(9-036) Assessment of Heparin Twice Daily versus Three Times Daily for Venous Thromboembolism Prevention

(9-037) Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Obesity

(9-053) Evaluation of Heparin Infusion Dosing Utilizing Actual Body Weight in Obese versus Non-Obese Patients

(9-055) Retrospective Comparison of Low Dose versus Standard Dose Unfractionated Heparin and Low Molecular Weight Heparin for Venous Thromboembolism Prophylaxis in Underweight, Hospitalized Patients

(9-072) Levels of Albumin and Impact on Loop Diuretic and Albumin Co-administration in Heart Failure (LILAC-HF)

(9-124) Evaluation of Transition of Thrombolytic Agent from Alteplase to Tenecteplase for Acute Ischemic Stroke Management

(9-127) Impact of Pharmacist Dosing Decisions on Effectiveness of Heparin Protocol for Treatment of Venous Thromboembolism in Obese versus Non-obese Patients

(9-138) Evaluation of Antithrombotic Management for Patients with Atrial Fibrillation and a History of Coronary Stent Implantation at an Outpatient Electrophysiology Clinic

(9-150) Evaluating the Efficacy and Safety of a Heparin Infusion Protocol for Patients Transitioning from Direct Oral Anticoagulants (DOAC)

(9-157) Clinical Outcomes of Initiating Sodium-Glucose Cotransporter 2 Inhibitors in Admitted Heart Failure Patients at a Large Academic Medical Center

(9-219) Methadone-Induced Torsades De Pointes in the Setting of Opioid Withdrawal

(9-226) Comparison of the Effectiveness, Safety, and Compliance to Inpatient Pharmacy Warfarin Protocols

(9-235) Evaluation of Heart Failure with Preserved Ejection Fraction Prescribing Practices Across a Five-Hospital Health System

(9-241) Safety of High-Dose Subcutaneous Heparin for Venous Thromboembolism Prophylaxis in Obese Inpatients

(9-242) Do Missed Doses of Pharmacologic Venous Thromboembolism (VTE) Prophylaxis Increase VTE Events in Trauma Patients with Pelvis, Acetabulum, and Femur Fractures?

(9-247) P2Y12 Inhibitor Use Associated with Coronary Stenting in Acute Coronary Syndromes

(9-248) Evaluation of the Management of Iron Deficiency in Patients with Heart Failure with Reduced Ejection Fraction Across a Five-Hospital Health System

(9-255) Impact of a Nurse-Driven Diuretic Protocol on Hospital Length of Stay in Patients with Acute Heart Failure Exacerbations

(9-273) Evaluation of Clotting Factor Product Utilization in a Large Health System

(9-301) Impact of Parenteral Bridging on Bleeding Outcomes in Patients Who Require Direct Oral Anticoagulant Interruption for an Elective Surgical Procedure

(9-316) Evaluation of Prophylactic Enoxaparin Use in Extreme Body Weights: A Retrospective Review

(9-337) Impact of Midodrine on Optimization of Beta-blocker Therapy in Heart Failure with Reduced Ejection Fraction (HFrEF) Patients

(9-361) Effectiveness of Pharmacist-Driven HF Discharge Checklist

(9-368) Guideline-Directed Medical Therapy in Patients with Heart Failure with Reduced Ejection Fraction: A Retrospective Chart Review on Appropriate Discharge Regimens

(9-369) Evaluating the Impact of Pharmacist-driven Intervention in Patients Receiving Heparin Infusions

(9-396) Comparison of a Weight-based Heparin Deep Vein Thrombosis and Pulmonary Embolism Treatment Protocol to a Cardiac Treatment Protocol in Achieving Therapeutic Activated Partial Thromboplastin Time

(9-407) Retrospective Evaluation of Perioperative Use of Intravenous Levothyroxine in Adult Heart Transplant Recipients

(9-427) Justification of a Hemostatic and Antithrombotic Stewardship Program at a Large Community Hospital

(9-450) Efficacy and Safety of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with a Left Ventricular Assist Device

(9-468) Common Drug-Drug Interactions in Patients with Atrial Fibrillation Anticoagulated with Factor Xa Inhibitors: Risk Factors for Bleeding - A Case-Control Study

(9-474) Evaluation of Guideline Directed Medical Therapy for Heart Failure with Reduced Ejection Fraction in Patients on Hemodialysis

(9-475) Assessing the Impact of a Dedicated Heart Failure Team on Guideline-Directed Medical Therapy Initiation During Hospitalization

(9-480) Evaluation of Fixed Dose Four Factor-Prothrombin Complex Concentrate (4F-PCC) in Patients with Oral Factor Xa Inhibitor-related Hemorrhage

(10-009) Assessing Pharmacist-led Perioperative Anticoagulation Management and Outcomes

(10-033) Evaluation of International Normalized Ratio Correlation Among Patients with Antiphospholipid Syndrome in Pharmacist Managed Anticoagulation Clinics

(10-046) Anti-Xa vs. aPTT: Evaluation of Heparin Monitoring Strategies

(10-064) Opportunities for Pharmacists to Improve Anticoagulation Dosing and Monitoring Following Discharge at a Community Hospital

(10-068) Evaluation of the Use and Appropriateness of Intravenous Antihypertensive Infusions in an Urban Safety Net Hospital

(10-071) Evaluation of Two Aspirin Doses for VTE Prophylaxis

(10-073) Evaluation of Andexanet Alfa Ordering and Administration Within a Community Health System

(10-074) Discontinuation of Heparin Products with a Pending Heparin-Induced Thrombocytopenia Antibody Test

(10-094) Empagliflozin and Dapagliflozin in Heart Failure with Reduced Ejection Fraction

(10-096) Evaluating the Efficacy and Safety of High-Dose Heparin for Prophylaxis of Venous Thromboembolism in Morbidly Obese Hospitalized Patients

(10-099) Lipid Lowering Therapy in Patients Following Acute Myocardial Infarction

(10-100) Tolerability of Rapid Initiation versus Traditional Sequencing of Guideline Directed Medical Therapy in Newly Diagnosed Patients with Heart Failure with Reduced Ejection Fraction

(10-116) Gastrointestinal Bleeds in Patients Receiving Therapeutic Anticoagulation with Direct Oral Anticoagulants or Warfarin: Evaluation with Odds Ratios of Patient Characteristics

(10-128) Retrospective Analysis of Opportunities to Convert from Warfarin to a Direct Oral Anticoagulant for Chronic Anticoagulation Therapy

(10-135) Therapeutic Assessment of High-Dose Initial Heparin Infusion for Patients in Stroke Therapy Protocol at Community Hospital

(10-145) Evaluating the Efficacy of Empagliflozin in Patients with Heart Failure with Reduced Ejection Fraction

(10-154) Decreased Heparin Bolus Leads to Decreased Bleeding with Impella® 5.0 or 5.5 Insertion

(10-161) Evaluation of Intravenous Loop Diuretic Use in Acute Decompensated Heart Failure in a Community Hospital

(10-172) Comparison of International Guidelines in the Management of Chronic Heart Failure with Reduced Ejection Fraction (HFrEF) and Its Associated Burden

(10-180) Appropriateness of Direct Acting Oral Anticoagulant Prescriptions in Patients with Atrial Fibrillation: Data from United Arab Emirates

(10-192) Evaluation of Pharmacist Driven Anti-Xa Monitoring of Enoxaparin in Obesity, Renal Disease, and COVID-19

(10-211) Anticoagulation Discharge Education by Pharmacists and Its Impact on Readmission Rates in a Large Community Hospital

(10-212) Bivalirudin vs Argatroban: Evaluating Time to First Therapeutic Activated Partial Thromboplastin Time (aPTT) Level and Ease-Of-Use

(10-228) Expansion of Lipid Lowering Therapy Optimization During Transitions of Care in Post-acute Myocardial Infarction (AMI) Patients

(10-230) Impact on Heart Failure Readmission Rates Through Pharmacist Driven Guideline Mediated Management and Titration in a Heart Failure Clinic

(10-236) Evaluation of Patient Outcomes Related to the Receipt of Alteplase versus Tenecteplase for Acute Ischemic Stroke in a Community Hospital

(10-254) Evaluation of Discharge Warfarin Regimens in Patients with a Supratherapeutic International Normalized Ratio (INR) on Admission

(10-273) Evaluation of Enoxaparin for Venous Thromboembolism Prophylaxis in Underweight Patients

(10-274) Assessing the Need for a Pharmacist-Led Warfarin Dosing Service in a Community-Based Academic Medical Center

(10-275) Evaluation of Sodium Bicarbonate-based versus Dextrose-based Purge Solution for Impella

(10-279) Efficacy and Safety of Dapagliflozin in Hospitalized Patients with Acute Heart Failure

(10-291) Impact of Post-Myocardial Infarction (MI) Depression on Cardiovascular-Related Hospitalizations

(10-294) Assessing the Impact of a Pharmacist Driven Discharge Counseling Service on 30-day Heart Failure Readmission Rates

(10-302) Safety of Enoxaparin versus Unfractionated Heparin for Venous Thromboembolism Prophylaxis in Critically Ill Patients with Renal Impairment

(10-316) Evaluating the Effectiveness of a Pharmacist-Driven Warfarin Protocol

(10-321) Effect on Time in Therapeutic Range Before and After Protocol Implementation for Patients Monitoring INR at Home

(10-325) Heparin Use in Medical/Surgical Patients Transitioned to a Direct Oral Anticoagulant During Hospitalization or at Discharge

(10-327) Assessing Institutional Enoxaparin Dosing Protocol Based on Anti-Xa Concentration in Special Populations

(10-337) Evaluation of the Implementation of a Weight Based Heparin MAR-Embedded Dosing Calculator on the Time to Achieve Therapeutic aPTT

(10-355) Implementation of a Pharmacy-Based Warfarin Consultation Service and Computerized Provider Order Entry (CPOE) in a State-Funded Hospital

(10-366) Impact of Increased Pharmacist Monitoring on Time in Therapeutic Range for Heparin Infusions

(10-382) Examination of Outcomes in Patients Prescribed Rivaroxaban After Peripheral Vascular Disease Revascularization Procedures

(10-383) Evaluating Pharmacist Impact on Guideline-Directed Medical Therapy in Patients with Heart Failure with Reduced Ejection Fraction or De Novo Systolic Dysfunction Following Acute Myocardial Infarction

(10-385) Increasing Utilization of Appropriate Heparin Monitoring Protocol in a Surgical Population

(10-396) Evaluation of Venous Thromboembolism Prophylaxis Dosing in the Low Body Weight Population

(10-397) Evaluation of Digoxin Loading Dose Strategies Across a Multi-Site Health System

(10-398) Impact of Initial Anticoagulation with Low Molecular Weight Heparin versus Unfractionated Heparin on Anticoagulation Failure in Acute Venous Thromboembolism

(10-409) Periprocedural Management of Direct Acting Oral Anticoagulants in Patients with Atrial Fibrillation

(10-415) Characterizing Prescribing Patterns of Enoxaparin and Assessing Adherence to Guideline-Directed Recommendations

(10-422) Apixaban Adherence

(10-431) Outcomes from Weight-based Intravenous Heparin Dosing in Morbid Obesity for Acute Coronary Syndromes, Atrial Fibrillation, Atrial Flutter, and Peripheral Artery Disease

(10-432) Evaluation of Adjusted Body Weight-Based Dosing of Unfractionated Heparin in Morbidly-Obese Patients for the Treatment of Acute Venous Thromboembolism

(10-436) Evaluation of DOAC Use Among Fragile Patients in VTE and AF

(10-438) An Evaluation of the Management of Warfarin and Continuous Tube Feeding Interactions at a Tertiary Academic Medical Center

(10-458) A Safety and Efficacy Evaluation of Institution Heparin Infusion Protocols

(10-467) Colchicine Safety and Effectiveness for Pericarditis in Patients with Severe Chronic Kidney Disease

(10-469) Evaluating the Effects of Capping Emergency Room Heparin Boluses for STEMI Patients Undergoing Percutaneous Coronary Intervention

(11-028) Impact of Heparin Dosing Weight on Bleeding Events in Obese Patients

(11-033) Assessment of Provider Knowledge and Therapeutic Approaches for Reducing Stroke Risk in Patients with Nonvalvular Atrial Fibrillation

(11-035) Assessing Adherence of Sacubitril-valsartan for Patients with Heart Failure

(11-063) Effects of Intravenous Iron Replacement on Heart Failure 30-Day Readmission Rates

(11-064) Assessing the Influence of COVID-19 on INR Therapeutic Range in Hospitalized Patients Receiving Warfarin

(11-070) Evaluation of Time to First Therapeutic Anti-Xa in Obese versus Nonobese Patients Using a Weight-Based Intravenous Heparin Dosing Protocol

(11-077) Impact of SGLT2 Inhibitor at Discharge Following Heart Failure with Reduced Ejection Fraction (HFrEF) Hospitalization After Hospital Formulary Addition

(11-079) Evaluation of Apixaban vs Rivaroxaban on Occurrence of Gastrointestinal Bleed in Patients on DOAC Therapy

(11-081) Effect of a Pharmacist Driven 4Ts Score Assessment in Streamlining Heparin Induced Thrombocytopenia Antibody Testing

(11-086) Reduced Dose versus Standard Dose Enoxaparin for VTE/PE Treatment in Obese Patients

(11-092) Evaluation of Initial Diuretics in Acute Decompensated Heart Failure

(11-102) Use of Post-operative Iron Supplementation in Cardiac Surgery

(11-103) Effects of Implementing a Heart Failure Order Set to Optimize Guideline-directed Medical Therapy and Diuresis in Patients with Acute Heart Failure

(11-138) Evaluation of New Sacubitril-Valsartan Administrations at a Community Hospital

(11-145) A Retrospective Evaluation of the Efficacy and Safety of Intensive Diuretic Interventions in Acute Decompensated Heart Failure

(11-170) Evaluation of Postoperative Glycemic Control in Cardiac Surgery Patients on an Intensive Insulin Infusion Protocol

(11-181) Assessment of a Weight-Based Heparin Dosing Protocol in Achieving an Initial Therapeutic Partial Thromboplastin Time

(11-200) Retrospective Safety Analysis Between Renal Dosing vs Standard Dosing for Venous Thromboembolism Prophylaxis Among Underweight Patients

(11-204) Impact of Beta-Blocker Selection on Hospital Admissions for Heart Failure

(11-224) Evaluation of Four Factor Prothrombin Complex Concentrate (4F-PCC) for Off-label Use in Patients Requiring Urgent Procedures

(11-229) Evaluation of the Impact of Overlapping Intravenous and Oral Amiodarone on Recurrent Atrial Fibrillation with Rapid Ventricular Response

(11-242) Comparison of Emergency Department versus Home Diuretic Doses on Efficacy and Safety Outcomes in Acute Decompensated Heart Failure

(11-250) Assessment of Enoxaparin Dose Adjustments in Venous Thromboembolism Prophylaxis in Morbidly Obese Patients with Body Mass Index Greater Than or Equal to 40 kg/m2

(11-254) Efficacy of Anticoagulants for Venous Thromboembolism (VTE) Prophylaxis in Obese Post-Total Hip and Knee Arthroplasty Patients

(11-262) Assessing the Effect of Pharmacist Discharge Counseling and Patient Outreach on Readmission Rates of Congestive Heart Failure Patients

(11-269) Cardiovascular Safety and Effectiveness of Sotalol Initiation at Higher Than Recommended Doses in Sotalol-Naïve Patients

(11-276) Evaluation of P2Y12 Inhibitor Utilization in Patients Admitted for Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

(11-294) Ensuring the Appropriate Use of Prothrombin Complex Concentrate in a Community Hospital

(11-299) Prescribing of Guideline-Directed Medical Therapy for Heart Failure with Reduced Ejection Fraction at Hospital Discharge: A Medication Use Evaluation

(11-310) Effectiveness of Once versus Twice Daily Intravenous Diuretic Dosing for Acute Decompensated Heart Failure

(11-354) Evaluation of the Use of Argatroban or Bivalirudin in the Treatment of Confirmed or Suspected Heparin-Induced Thrombocytopenia at a Large Academic Medical Center

(11-355) Evaluation of 4-factor Prothrombin Complex Concentrate (4F-PCC) Use at a Large Medical Center